Shenzhen Hepalink Pharmaceutical Group 2025 Annual Report: Key Insights for Investors

Financial Performance: Recovery and Dividend Proposal

• Revenue and Profit: The Group reported a revenue of RMB 5.44 billion in 2025, representing a modest rebound from RMB 5.26 billion in 2024, after a significant drop in 2023. Profit attributable to equity holders was RMB 349.5 million, down 46% from RMB 646.7 million in 2024. Earnings per share decreased to RMB 0.24 from RMB 0.44.
• Dividend: The Board proposes a final cash dividend of RMB 1.45 per ten ordinary shares (tax inclusive), down from RMB 2.5 in 2024. This is subject to shareholder approval at the upcoming AGM.
• Asset-Liability Ratio: The Group’s asset-liability ratio improved to 27% (from 30% in 2024), with total assets at RMB 16.63 billion and total liabilities at RMB 4.55 billion.
• Finance Costs: Finance costs dropped sharply by 48.5% to RMB 74.7 million due to reduced interest-bearing debt and lower borrowing rates.
• Taxation: Income tax expense decreased to RMB 59.6 million from RMB 101.3 million.

Operational Highlights and Risks

• Business Focus: Hepalink remains heavily dependent on two main products—enoxaparin sodium injection and heparin sodium API.
• CDMO Business: The CDMO (Contract Development and Manufacturing Organization) segment is sensitive to customer spending and demand for biologics discovery, development, and manufacturing. Any reduction in client budgets could significantly impact Hepalink’s financial performance and outlook.
• Regulatory and Pricing Risks: Some products are subject to government price controls and reimbursement policies, which could adversely affect revenues and profits if not maintained.
• Production Risks: Disruption at production sites or quality issues could negatively affect reputation and financial results.
• Goodwill Impairment: Goodwill represents a substantial portion of assets; any impairment would materially impact financials.

Capital Management and Resource Allocation

• Capital Structure: The Group actively manages its capital structure, reviewing debt-to-asset ratios and responding to changes in economic conditions, profitability, and cash flows. As of year-end, 63.7% of interest-bearing borrowings were at fixed rates.
• Use of H-Share Listing Proceeds: Of the RMB 3.54 billion raised in the 2020 Hong Kong listing, approximately RMB 52.8 million remains unutilized. The Board proposes reallocating these funds to supplement general working capital, instead of further innovative drug investment, citing market changes and capital allocation efficiency.

Corporate Governance, Compliance, and Shareholder Matters

• Governance: Hepalink complies with all relevant laws, regulations, and the Corporate Governance Code of Hong Kong. No material non-compliance was reported in the year.
• No Material Legal Proceedings: The Group was not involved in any significant litigation or legal proceedings during the reporting period.
• Major Customers and Suppliers: The largest customer accounted for 13.12% of total revenue; the five largest customers accounted for 31.19%. The largest supplier accounted for 18.39% of purchases; the five largest suppliers for 36.42%. No director, close associate, or major shareholder (>5%) had an interest in these parties.
• Share Capital and Reserves: No purchase, sale, or redemption of listed securities occurred. Distributable reserves as of year-end were RMB 224.1 million.
• Retirement Benefits: The Group fulfills its obligations for employee retirement benefits schemes, with no additional liabilities beyond specified contributions.
• Non-Competition Undertakings: Controlling shareholders have complied with non-competition agreements, as confirmed by independent non-executive directors.

Fair Value and Financial Risk Management

• Valuation Techniques: Unlisted equity investments are valued using market-based approaches, including precedent transactions, binomial tree models, and guideline public company methods. Key unobservable inputs include price-to-sales ratios (up to 15.17x) and discounts for lack of marketability (up to 30%).
• Sensitivity: A 5% change in unobservable inputs could impact the fair value of certain assets by millions of RMB.
• Risk Management: The Group actively manages interest rate, foreign exchange, credit, and liquidity risks. Treasury policies are in place to maintain funding and manage capital structure.
• Interest Rate Sensitivity: A 100 basis-point shift would change pre-tax profit and equity by RMB 10.5 million.

Environmental, Social, and Governance (ESG)

• ESG Commitment: Hepalink has detailed internal rules for environmental protection, including air, water, solid waste discharge, and noise control. No material violations or environmental compliance costs were reported.
• Anti-Corruption: No material incidents of bribery, fraud, or money laundering occurred. The Group maintains strict anti-corruption policies.
• Shareholder Communication: A comprehensive shareholder communication policy is in place. The company maintains a website and email contact for investor enquiries.

Price-Sensitive and Shareholder-Relevant Matters

• Dividend Cut Could Affect Share Price: The reduction of the final cash dividend from RMB 2.5 in 2024 to RMB 1.45 in 2025 signals a weaker profit outlook and may be price sensitive.
• Profit Decline: A nearly 50% drop in profit attributable to shareholders may negatively impact market sentiment.
• Change in Use of H-Share Proceeds: The reallocation of unutilized proceeds from innovative drug development to working capital reflects a shift in strategic priorities and may affect investor expectations regarding growth and R&D investment.
• Business Dependency and Risks: Continued reliance on two products and exposure to government pricing and reimbursement policies represent concentration risks that could affect future revenue and share value.
• CDMO Sensitivity: Any downturn in client spending in the CDMO business could materially impact financial performance and market valuation.

Conclusion

Shenzhen Hepalink Pharmaceutical Group’s 2025 annual report reveals a company facing significant profit pressure, dividend reduction, and strategic shifts in capital allocation. Shareholders should closely monitor the company’s dependency on core products, sensitivity to regulatory and client risks, and the impact of reduced profitability on future dividends and share value. The proposal to reallocate H-share proceeds away from innovative drug investment may signal a more conservative approach in a changing market environment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making investment decisions. All information is based on the company’s 2025 annual report and subject to AGM approval and future announcements.

View HEPALINK Historical chart here